Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gaucher disease: Perspectives on a prototype lysosomal disease.

H Zhao1, G A Grabowski

  • 1Division and Program in Human Genetics, Cincinnati Children's Hospital Medical Center, Ohio 45229-3039, USA.

Cellular and Molecular Life Sciences : CMLS
|May 23, 2002
PubMed
Summary

Gaucher disease, a common lysosomal storage disorder, stems from reduced acid beta-glucosidase activity, causing glucosylceramide buildup. Enzyme replacement therapy is effective, but its precise mechanisms require further research for better understanding and treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Accumulation and distribution of α-synuclein and ubiquitin in the CNS of Gaucher disease mouse models.

Molecular genetics and metabolism·2011
Same author

Genotype-phenotype correlations in Rubinstein-Taybi syndrome.

American journal of medical genetics. Part A·2008
Same author

Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring.

Journal of inherited metabolic disease·2008
Same author

Prosaposin is an AR-target gene and its neurotrophic domain upregulates AR expression and activity in prostate stromal cells.

Journal of cellular biochemistry·2008
Same author

Recommendations for the assessment and monitoring of skeletal manifestations in children with Gaucher disease.

Skeletal radiology·2007
Same author

The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease.

Clinical genetics·2007

Area of Science:

  • Biochemistry
  • Genetics
  • Cell Biology

Background:

  • Gaucher disease is the most common autosomal recessive lysosomal storage disease.
  • It results from deficient acid beta-glucosidase activity, leading to glucosylceramide accumulation in lysosomes.
  • The precise pathogenic mechanisms remain incompletely understood.

Purpose of the Study:

  • To review the current understanding of Gaucher disease's molecular pathogenesis.
  • To highlight knowledge gaps and future research directions.
  • To discuss the efficacy of enzyme replacement therapy (ERT).

Main Methods:

  • Literature review of biochemical and molecular biology studies.
  • Analysis of current knowledge on Gaucher disease pathogenesis.

Related Experiment Videos

  • Evaluation of enzyme replacement therapy effectiveness.

    • Main Results:

    • Significant progress in understanding the biochemical and molecular basis of Gaucher disease over the past two decades.
    • Enzyme replacement therapy has demonstrated success in managing Gaucher disease.
    • Fundamental knowledge gaps persist in linking molecular advances to cellular and systemic phenotypes.

    Conclusions:

    • Further fundamental research is crucial to fully elucidate the relationship between molecular mechanisms and disease phenotypes in Gaucher disease.
    • Elucidation of the basic details underlying the therapeutic efficacy of ERT is needed.
    • Gaucher disease serves as a prototype for advancing research in lysosomal storage diseases.